CLAIMS:

1. A peptide mixture suitable for eliciting an immune response comprising a first, second, third, fourth, fifth, sixth, seventh and eighth peptide, each corresponding to a fragment of the RAS protein wherein:

the first, second, third, fourth, fifth, sixth, seventh and eighth peptides are:

a peptide comprising the amino acid sequence of SEQ ID NO: 19,

a peptide comprising the amino acid sequence of SEQ ID NO: 20,

a peptide comprising the amino acid sequence of SEQ ID NO: 21,

a peptide comprising the amino acid sequence of SEQ ID NO: 22,

a peptide comprising the amino acid sequence of SEQ ID NO: 23,

a peptide comprising the amino acid sequence of SEQ ID NO: 24,

a peptide comprising the amino acid sequence of SEQ ID NO: 25, and

a peptide comprising the amino acid sequence of SEQ ID NO: 26,

and wherein each of the peptides comprises no more than 30 amino acids.

2. A peptide mixture according to claim 1, wherein each of the first, second, third, fourth, fifth, sixth, seventh and eighth peptides comprises no more than 28, 26, 24, 22, 20 or 18 amino acids.

3. A peptide mixture according to claim 1 or 2, wherein the first, second, third, fourth, fifth, sixth, seventh and eighth peptides are:

a peptide consisting of the amino acid sequence of SEQ ID NO: 19,

a peptide consisting of the amino acid sequence of SEQ ID NO: 20,

a peptide consisting of the amino acid sequence of SEQ ID NO: 21,

a peptide consisting of the amino acid sequence of SEQ ID NO: 22,

a peptide consisting of the amino acid sequence of SEQ ID NO: 23,

a peptide consisting of the amino acid sequence of SEQ ID NO: 24,

a peptide consisting of the amino acid sequence of SEQ ID NO: 25, and

a peptide consisting of the amino acid sequence of SEQ ID NO: 26.

4. A T-cell mixture comprising T-cells specific for each of the peptides in the peptide mixture according to any one of claims 1-3, when presented on an MHC molecule.

5. A pharmaceutical composition comprising the peptide mixture of any one of claims 1-3, or the T-cell mixture of claim 4 and a pharmaceutically acceptable carrier, diluent and/or excipient.

6. A peptide mixture according to any one of claims 1-3, a T-cell mixture according to claim 4 or a pharmaceutical composition according to claim 5 for use in the prophylaxis and/or treatment of cancer in a patient.

7. A peptide mixture according to any one of claims 1-3, a T-cell mixture according to claim 4 or a pharmaceutical composition according to claim 5, for use in the prophylaxis and/or treatment of cancer, wherein the cancer is colorectal, lung and/or pancreatic cancer.

8. A peptide mixture, a T-cell mixture, or a pharmaceutical composition for use according to claim 6, wherein said prophylaxis and/or treatment comprises

identifying RAS protein amino acid substitutions present in a sample taken from the patient.